Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,304
datasets available to search
ShareScore release 0.9.0
Dataset results
1,304 results for “Cognitive impairments”
NMR based clinical metabolomics study revealed aberrant proline biosynthesis and mitochondrial dysfunction in patients of mild cognitive impairment
<p>The prevalence of type-2 diabetes mellitus (T2DM) is tremendously increasing in older population because of several reasons and studies have shown that such old-age T2DM patients have 50-65% higher risk of developing cognitive impairment and its progression towards mild cognitive impairment (MCI). The studies claim that in the majority of MCI patients, the diabetes selectively involves the brain and the condition is now considered as a neuroendocrine disorder, even referred to as type 3 diabetes (T3D). Impaired glucose metabolism and mitochondrial dysfunction in neurodegenerative diseases, particularly in MCI, is compelling. Therefore, clinical interest is emerging to understand the role of mitochondria in T2DM and T3D which may provide important insights into pathogenesis of such chronic diseases and may indeed provide a target for improved patient care. The present study, therefore, aims to compare the serum metabolic profiles of MCI patients with age and sex matched T2DM patients with respect to normal control (NC) subjects. The results revealed that abnormal glutamate-to-glutamine cycling and proline metabolism in MCI patients. Compared to T2DM patients, the elevated circulatory proline levels in MCI patients hinted towards abnormal mitochondrial functioning underlying cognitive impairment.</p>
Dataset for "Sulcal Morphometry Predicts Mild Cognitive Impairment Conversion to Alzheimer's Disease"
<p>The dataset contains the numerical data described and analyzed in the paper "Sulcal Morphometry Predicts Mild Cognitive Impairment Conversion to Alzheimer’s Disease", Sighinolfi et al., J Alzheimers Dis, 2024, doi: 10.3233/JAD-231192.</p> <p>It consists of the measures, performed using the Morphologist software, of the morphological properties of brain sulci in 87 subjects, as described in the paper.</p> <p>If interested in the data, please contact the Corresponding Author: <br>Prof. Caterina Tonon<br>caterina.tonon@unibo.it</p>
Dataset related to the article "Relation between anticholinergic burden and cognitive impairment: Results from the Monzino 80-plus population-based study"
<p><em>The file contains raw data related to the article "Relation between anticholinergic burden and cognitive impairment: Results from the Monzino 80-plus population-based study", available from <a href="https://onlinelibrary.wiley.com/doi/10.1002/pds.5159">https://onlinelibrary.wiley.com/doi/10.1002/pds.5159</a>.</em></p> <p> </p> <p><strong>Abstract of the manuscript:</strong></p> <p><strong>Purpose: </strong>We examined data collected in the Monzino 80-plus study to assess the relations between cognitive performance and ACB scores according to the hypothesis that a higher anticholinergic burden is associated with reduced cognitive performance.</p> <p><strong>Methods: </strong>The Monzino 80-plus is an ongoing, prospective, door-to-door population-based study started in 2002 among all residents 80 years or older in eight municipalities of Varese province, Italy. To establish the relation between cognitive impairment and the anticholinergic drug burden we recorded the ACB score for each patient at baseline. The relations between ACB score and dementia or MMSE scores were also examined after exclusion of patients taking any antipsychotic.</p> <p><strong>Results: </strong>A sample of 2140 elderly people was eligible for analysis. A significant dose-effect relationship was observed between total ACB score and diagnosis of dementia in univariate and multivariate models. Patients in ACB class ≥4 had about 4.5 times the risk of diagnosis of dementia. A relation was also found between higher ACB scores and lower MMSE scores; patients who scored 4 or more had a mean of 6.4 points lower than those not taking anticholinergic drugs. The dose-effect relationship between ACB score and diagnosis of dementia was not maintained after exclusion of patients using antipsychotics, while the association between higher ACB scores and lower MMSE scores was still present, with patients in ACB class ≥4 having a mean score about 4.4 lower.</p> <p><strong>Conclusions: </strong>There are clear relations between anticholinergic load and reduced cognitive performance, while the association with dementia remains uncertain. For primary care and geriatric clinicians, an ACB score ≥ 4 can be considered the cut-off to identify high-risk populations who may benefit from the evaluation of anticholinergic burden with the ACB scale.</p>
TARGETING NEURONAL FTL1 RESCUES COGNITIVE IMPAIRMENTS IN AGING
GEO Series GSE249504. Mus musculus. 4 samples. Type: Expression profiling by high throughput sequencing.
Maternal immune activation impairs cognitive flexibility and alters transcription in frontal cortex
GEO Series GSE137497. Mus musculus. 17 samples. Type: Expression profiling by high throughput sequencing.
RNA-seq from CD4 T lymphocytes of cirrhotic patients with cognitive impairment
GEO Series GSE184200. Homo sapiens. 20 samples. Type: Expression profiling by high throughput sequencing.
Extracellular vesicles from epicardial fat mediate long-distance heart-brain communication and promote atrial fibrillation associated cognitive impairment (EAT exosomal miRNA-seq and hippocampal mRNA-
GEO Series GSE240776. Canis lupus familiaris. 12 samples. Type: Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing.
microRNA microarray profile in the plasma of mild cognitive impairment due to Alzheimer's disease
GEO Series GSE147232. Homo sapiens; Rattus norvegicus; Mus musculus. 10 samples. Type: Non-coding RNA profiling by array.
Repeated exposure to lidocaine induces hippocampal synaptic and cognitive impairment in aged mice by activating microglia and neurotoxic A1astrocytes
GEO Series GSE270941. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Characteristic of the transcriptomics in the early subcortical vascular cognitive impairment [miRNA-Seq]
GEO Series GSE201481. Homo sapiens. 20 samples. Type: Non-coding RNA profiling by high throughput sequencing.
Phlorizin ameliorates cognitive and behavioral impairments via the microbiota-gut-brain axis in diet-induced obese mice
GEO Series GSE261887. Mus musculus. 18 samples. Type: Expression profiling by high throughput sequencing.
Characteristic of the transcriptomics in the early subcortical vascular cognitive impairment
GEO Series GSE201483. Homo sapiens. 40 samples. Type: Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing.
Butylphthalide may inhibit blood-brain barrier disruption through complement-related pathways to alleviate cognitive impairment in epileptic mice
GEO Series GSE277743. Mus musculus. 9 samples. Type: Expression profiling by high throughput sequencing.
Alzheimer’s disease-associated U1 snRNP splicing dysfunction causes neuronal hyperexcitability and cognitive impairment
GEO Series GSE196873. Mus musculus. 28 samples. Type: Expression profiling by high throughput sequencing.
RNA sequencing analysis Reveal Post-Stroke Cognitive Impairment related genes in Hippocampus of Cerebral Ischemic Rat
GEO Series GSE160290. Hippocampus. 6 samples. Type: Expression profiling by high throughput sequencing.
Gait characteristics under different walking conditions: Association with the presence of cognitive impairment in community-dwelling older people.
<p>This dataset contains Demographics, physical and gait characteristics on older persons with cognitive complaints tested in five walking conditions</p>
Frontal Atrophy and CSF Tau Levels With Neuropsychiatric Symptoms in Patients With Cognitive Impairment
<p>This database includes the raw data linked with the paper “ Frontal Atrophy and CSF Tau Levels With Neuropsychiatric Symptoms in Patients With Cognitive Impairment: A Memory Clinic Experience. ” published on “ Frontiers in Aging Neuroscience 5, March, 2021”.</p> <p>Behavioral and psychological symptoms of dementia (BPSD) are a distressful condition. We aimed to investigate the BPSD distribution in subjects with cognitive impairment, and the potential correlations between BPSD and neurodegeneration in terms of cerebrospinal fluid (CSF) tau and brain atrophy.</p> <p>One-hundred patients with mild cognitive impairment (MCI) or dementia (Alzheimer’s disease; Lewy-body disease, LBD; frontotemporal dementia; vascular dementia) underwent a complete diagnostic workup, including 3T-MRI and/or CT and CSF.</p> <p>Cortical atrophy was assessed with MTA, PA and GCA-F scales. BPSD were rated using Neuropsychiatric Inventory (NPI), and BPSD clusters were defined according to the European Alzheimer Disease Consortium.</p> <p>Delusions, hallucinations and psychosis cluster were differently distributed among the diagnostic groups (p<0.05, p<0.001, and p<0.05), with LBD patients showing higher scores for hallucinations (vs MCI, p<0.001, and AD, p<0.05) and psychosis cluster (vs MCI, p<0.05). In primary dementias, we found a negative trend between NPI total score and tau levels (p=0.08), while a positive relationship was observed in MCI (p=0.60). Higher GCA-F scores were associated to delusions and apathy (p<0.05, on both hemispheres) and to hallucinations (left: p<0.01, right: p<0.05). GCA-F scores were positively correlated with delusions and psychosis cluster (right: p<0.05), and agitation/aggression (left: p<0.05). Conversely, nighttime disturbances were positively correlated with both GCA-F and MTA scores (left: p<0.01; right: p<0.05).</p> <table align="left"> <tbody> <tr> <td> <p> </p> </td> </tr> </tbody> </table>
Analysis of inflammatory predictors and differences in gene expression in patients with Cognitive Impairment Mild responders and non-responders to Neurostimulation: a randomized, double-blind clinical trial
<p>https://docs.google.com/spreadsheets/d/1jUrBFxUs57HBCj-y0NkID1kzdnsLPpr9/edit#gid=788062431</p> <p>Mild cognitive impairment (MCI) refers to the transition state between the cognitive changes of normal aging and early dementia, but it does not notably interfere with activities of daily living. MCI is believed to be a prodromal stage of dementia that causes severe cognitive dysfunction, so its identification for early intervention is considered an important therapeutic strategy.<br> In this context, non-pharmacological interventions, such as Transcranial Direct Current Stimulation (tDCS), which uses direct electrical currents to stimulate specific parts of the brain, have been used to clinically improve these patients. Biochemical processes have been linked to the pathogenesis of MCI and dementia, including chronic inflammation, dysregulation of membrane lipids, disruption of neurotransmitter pathways, and mutations in specific genes. Therefore, the general objective of this study is to evaluate the inflammatory and gene expression profile of patients with MCI, responders and non-responders to tDCS. This is a randomized, double-blind, sham-controlled clinical trial (ClinicalTrials.org: NCT04934423).<br> Neuropsychological tests and a sociodemographic and clinical questionnaire will be used to assess and characterize the subjects. Participants captured by the Laboratory of Studies in Aging and Neurosciences of the Federal University of Paraíba will be divided into 02 groups, each with 25 patients, totaling 50 volunteers: Active – participants who will receive real anodic current; Sham – participants who will receive simulated stimulation. Participants enrolled by eligibility criteria will be randomly allocated in a simple 1:1 ratio. The equipment parameters will be customized by Computational Modeling with the help of the Non-Invasive Brain Stimulation Simulation Program and the measurement of the head circumference. The electroencephalogram and the evaluation of polymorphisms of the genes Alpha synuclein and Neuroregulin, as well as the inflammatory mediators IL-6, Il-10 and TNF-α, will be considered as possible predictors of response. The project was evaluated by the Research Ethics Committee of the Federal University of Paraíba, obtaining the following CAAE registration: 40675220.0.0000.5188. It is expected to find improvements in the scores of general cognition and memory tests after the intervention protocol of neurostimulation with an individual dose in the group that will receive the active current, compared to the simulated neurostimulation group. As well as finding differences in the Inflammatory and Genetic profiles of those responders and non-responders to Neurostimulation.</p>
Dataset concerning A double-blind randomized controlled trial combining cognitive training (CoRe) and neurostimulation (tDCS) in the early stages of cognitive impairment
<p>This is the processed data for the manuscript " Rodella C, Bernini S, Panzarasa S, Sinforiani E, Picascia M, Quaglini S, Cavallini E, Vecchi T, Tassorelli C, Bottiroli S. A double-blind randomized controlled trial combining cognitive training (CoRe) and neurostimulation (tDCS) in the early stages of cognitive impairment. Aging Clin Exp Res. 2021 Jun 22. Epub ahead of print".</p> <p>Dataset refers to a Randomized Controlled Trial aimed to evaluate the effectiveness of a combined treatment protocol associating a computerized cognitive training (CoRe) with anodal transcranial direct current stimulation (tDCS) in early phases of cognitive impairment. The dataset contains cognitive performances in neuropsychological tests (raw scores) at baseline (T0), post-intervention (T1) and 6-months later (T2). Data highlights the efficacy of combining cognitive training and neurostimulation.</p>
Characteristic of the transcriptomics in the early subcortical vascular cognitive impairment [RNA-Seq]
GEO Series GSE201482. Homo sapiens. 20 samples. Type: Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.